Multibagger Selection: DeepSeek's picks
DeepSeek picked UMAC, INOD, KRMN, SEZL, BCRX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | UMAC | — | 72% | — | — |
| 2 | INOD | — | 74% | — | — |
| 3 | KRMN | — | 70% | — | — |
| 4 | SEZL | — | 68% | — | — |
| 5 | BCRX | — | 66% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -3.28% | -2.66% | 1.16x | 0 |
The model's market view
The current environment for small and mid-cap multibagger candidates favors companies with visible revenue acceleration, expanding gross margins, and a specific, time-bound catalyst that changes the earnings trajectory. The Fed's growth scare has compressed valuations for speculative names, but names with tangible operating leverage and contracted demand are being rewarded. I prioritize companies where the inflection is already visible in reported numbers and where the next 12 months contain a verifiable event (contract conversion, product launch, regulatory decision) that can force upward estimate revisions. I avoid names where the thesis depends solely on multiple expansion or an unverified future order.
Why each pick
UMAC
Unusual Machines is the most explosive small-cap growth story in the set: Q2 2026 revenue surged 687% year over year to $16.7 million, and management guided FY2026 revenue growth of 432%, with FY2027 growth of 94% expected. The company is a pure-play beneficiary of the U.S. push to onshore drone manufacturing, and the recent Northland initiation with an Outperform rating and a $30 target on October 23 provides fresh market confirmation. Gross margin improved sequentially to 34.7% in Q2 2026 from 32.8% in Q1, and management expects recovery toward 40% as growth normalizes. The market cap of $812.79 million leaves substantial room for appreciation if the revenue ramp continues, but the stock is volatile and the 432% growth rate is unlikely to persist beyond 2026. The key risk is that the drone procurement cycle slows or that competition compresses margins. Reverse valuation: 3x requires revenue near $200 million with a 12x P/S, plausible given the current trajectory; 5x requires $300 million revenue and a 13x P/S, exceptional; 10x requires $500 million revenue and a 16x P/S, extreme.
INOD
Innodata has one of the cleanest operating inflections in small-cap AI: Q2 2026 revenue rose 58% to $92.1 million, adjusted gross margin expanded to 49% from 43% a year earlier, and adjusted EBITDA jumped 96%. Management raised FY2026 revenue growth guidance to approximately 40% or more, up from 35%, and the company has now delivered 12 consecutive quarters of annual growth. The catalyst is the broadening of AI data-engineering demand beyond a single large customer; management has secured major new contracts and accelerated customer diversification. At a $2.05 billion market cap, the stock trades at roughly 5.5x annualized Q2 2026 revenue, which is modest for a company with 40%+ growth and 49% gross margins. The main risk is customer concentration: a significant portion of revenue still comes from a few large AI customers, and any pause in their spending would hit growth. Reverse valuation: 3x requires revenue near $600 million with a 10x P/S, plausible; 5x requires $800 million revenue and a 12.5x P/S, exceptional; 10x requires $1.2 billion revenue and a 17x P/S, extreme.
KRMN
Karman Space & Defense is a defense-growth compounder with a record $1.3 billion backlog, up 65% year over year, and Q2 2026 revenue of $182.1 million, up 58% year over year (24.4% organic). Management raised FY2026 revenue guidance to $730–$745 million and adjusted EBITDA guidance to $215–$222.5 million, implying a 29.7% margin at the midpoint. The catalyst is the conversion of the record backlog into revenue over the next 12 months, supported by U.S. defense priorities in hypersonics and missile defense. Oppenheimer initiated coverage with an Outperform rating on October 22, 2026, providing fresh market confirmation. At a $4.58 billion market cap, the stock trades at roughly 6.2x annualized Q2 2026 revenue, which is reasonable for a defense company with 25%+ organic growth and expanding margins. The main risk is program timing: defense budgets can shift, and the backlog conversion could slip. Reverse valuation: 3x requires revenue near $1.8 billion with a 7.5x P/S, plausible; 5x requires $2.5 billion revenue and a 9x P/S, exceptional; 10x requires $4 billion revenue and a 11x P/S, extreme.
SEZL
Sezzle is a high-growth fintech with Q2 2026 revenue of $149.7 million, up 51.7% year over year, net income of $40.8 million (27.2% margin), and adjusted EBITDA of $58 million (38.8% margin). Management raised FY2026 revenue growth guidance to 30–35% and has consistently beaten estimates. The catalyst is the subscriber pivot and product expansion, which is driving higher purchase frequency and platform engagement; the company raised guidance on August 7, 2026, and the stock has strong market confirmation with a beta of 6.73 and rising institutional interest. At a $4.7 billion market cap, the stock trades at roughly 7.9x annualized Q2 2026 revenue and about 28x trailing earnings, which is reasonable for a company growing revenue 50% with 27% net margins. The main risk is consumer credit: a weakening economy could increase delinquencies and compress margins. Reverse valuation: 3x requires revenue near $1.8 billion with a 7.8x P/S, plausible; 5x requires $2.5 billion revenue and a 9.4x P/S, exceptional; 10x requires $3.5 billion revenue and a 13.4x P/S, extreme.
BCRX
BioCryst Pharmaceuticals is a profitable biotech with a durable revenue engine in ORLADEYO and a fresh FDA catalyst. Q2 2026 revenue reached $218.3 million, with gross margin of 77.4% and positive cash flow independent of licensing receipts. The FDA approved a new oral pellet formulation of ORLADEYO on October 21, 2026, extending the franchise's lifecycle and improving patient convenience. The stock trades at roughly $2.0 billion market cap, or about 2.2x annualized Q2 2026 revenue, which is deeply undervalued for a company with 36% revenue growth and 77% gross margins. The catalyst is the launch of the pellet formulation, which can drive incremental prescriptions and extend patent protection. The main risk is competition from newer oral therapies and the company's historical dependence on a single product. Reverse valuation: 3x requires revenue near $2.5 billion with a 2.4x P/S, plausible; 5x requires $3.5 billion revenue and a 2.8x P/S, exceptional; 10x requires $5 billion revenue and a 4x P/S, extreme.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | BKSY, LPTH, INOD, LMND, OUST |
| Gemini 3 Pro | RKLB, SOUN, LUNR, RXRX, ACHR |
| Grok 4.7 | NTLA, VKTX, ONDS, LUNR, MGTX |
| Muse Spark 1.1 | BHVN, EOSE, CAPR, SERV, MSM |
| GPT-6 | INOD, ACMR, ADMA, AMSC, TMDX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.